注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Tempest Therapeutics Inc(Tempest)是一家临床阶段的肿瘤公司。该公司专注于开发结合靶向和免疫介导机制来治疗各种肿瘤的疗法。该公司的两个临床项目为TPST-1495和TPST-1120。TPST-1120是过氧化物酶体增殖物激活受体的选择性拮抗剂。TPST-1120正处于实体瘤的 I 期和 II 期试验中,包括一项全球随机Ib/II期试验,联合标准一线治疗方案atezolizumab和贝伐单抗治疗晚期或转移性肝细胞癌。TPST-1495是EP2和EP4(前列腺素E2受体)的双重拮抗剂,目前正处于实体瘤的I期单一疗法和联合试验中。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Petpiboon Prasit | - | - | Acting Chief Scientific Officer & Executive Director |
Michael G. Raab | 58 | 2019 | Independent Chairman |
Drew Mark Pardoll | - | - | Member of Advisory Board |
Benjamin F. Cravatt | 53 | 2019 | Member of Advisory Board |
Jason J. Luke | - | - | Member of Advisory Board |
Geoffrey M. Nichol | 68 | 2021 | Independent Director |
Petpiboon Prasit | - | - | Member of Advisory Board |
Christine A. Pellizzari | 55 | 2021 | Independent Director |
Russell Vance | - | 2021 | Member of Advisory Board |
Toni K. Choueiri | - | - | Member of Advisory Board |
Raymond N. DuBois | 68 | - | Member of Advisory Board |
Ronit Simantov | 58 | 2021 | Independent Director |
Stephen R. Brady | 53 | 2021 | CEO, President & Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核